生血宁片联合罗沙司他治疗维持性血液透析患者贫血临床研究

Study on Shengxuening Tablets combined with roxadustat in treatment of anemia in patients on maintenance hemodialysis

目的观察生血宁片联合罗沙司他治疗维持性血液透析贫血(MHDA)临床疗效。方法将我院120例MHDA患者随机分为观察组与对照组各60例。对照组给予罗沙司他治疗,观察组给予生血宁片联合罗沙司他治疗。比较两组临床疗效,贫血指标血红蛋白(Hb)、血细胞比容(Hct)、红细胞计数(RBC),血脂指标总胆固醇(TC)、低密度脂蛋白胆固醇脂(LDL),微炎症指标C反应蛋白(CRP)、白介素-6(IL-6),铁代谢指标血清铁(SI)、转铁蛋白饱和度(TSAT),肾功能指标血清尿素氮(BUN)、血清肌酐(Scr)、24 h尿蛋白排泄率(UPE),中医证候评分(主症、次症、总分)。结果治疗后,观察组总有效率高于对照组(P<0.05);两组Hb、Hct、RBC、SI、TSAT水平均高于治疗前,观察组Hb、Hct、RBC、SI、TSAT水平均高于对照组(P<0.05);两组TC、LDL、CRP、IL-6、BUN、Scr、24 hUPE水平,中医证侯评分低于治疗前,观察组上述指标均低于对照组(P<0.05)。结论生血宁片联合罗沙司他治疗MHDA疗效较好,可纠正铁缺乏,促进造血,降低血脂,提高肾功能,改善中医证候和微炎症状态。

Objective To observe the clinical effect of Shengxuening Tablets combined with roxadustat in treatment of maintenance hemodialysis anemia(MHDA).Methods A total of 120 MHDA patients were randomly divided into study group and control group,with 60 cases in each group.Control group was treated with roxadustat,and study group was treated with Shengxuening Tablets on the basis of control group.The clinical efficacy,anemia indicators[hemoglobin(Hb),hematocrit(Hct),red blood cell count(RBC)],blood lipid indicators[total cholesterol(TC),low-density lipoprotein cholesterol lipid(LDL)],microinflammation indicators[C-reactive protein(CRP),interleukin-6(IL-6)],iron metabolism indicators[serum iron(SI),transferrin saturation(TSAT)],renal function indicators[serum urea nitrogen(BUN),serum creatinine(Scr),24 h Urine protein excretion rate(UPE)]and TCM syndrome score(main symptom,secondary symptom,total score)of the two groups were compared.Results After treatment,the total effective rate of study group was higher than that of the control group(P<0.05);the levels of Hb,Hct,RBC,SI,and TSAT in both groups were higher than those before treatment,and were higher in study group than those in control group(P<0.05);the levels of TC,LDL,CRP,IL-6,BUN,Scr,and 24 hUPE in both groups were lower than those before treatment,and were lower in study group than control group(P<0.05).Conclusion Shengxuening Tablets combined with roxadustat can correct iron deficiency,promote hematopoiesis,reduce blood lipids,improve renal function,and improve TCM syndrome and micro-inflammatory status in treatment of MHDA.